{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:20:30Z","timestamp":1783376430054,"version":"3.54.6"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:p>Renal dysfunction causes dyslipidemia, and the progression of kidney disease is associated with treatment-requiring lipid disorders. However, there is little data on the association between the severity of dyslipidemia and various treatment modalities with renal function. A total of n\u2005=\u2005214 prevalent patients from a lipidology and nephrology practice were investigated in an unicentric cross-sectional study and divided into 4 groups based on the severity and therapeutic regimen of an existing lipid metabolism disorder: a lipid apheresis-treated group (LA), a drug-treated group (MG), a control group (CG) that included patients with lipid disorder not needing any treatment, and a diabetes group that comprised all diabetes patients. We examined fat metabolism parameters, renal parameters and urinary protein excretion, and compared these between study groups. Lipid apheresis therapy leads to the effective lowering of low density lipoprotein-concentration and to a reduction in the presumably protective high density lipoprotein-concentration. We found that S-crea was significantly higher in the LA, MG, and diabetes group than in the CG, while electronic glomerular filtration rate (eGFR) was correspondingly lower. On the other hand, proteinuria was not elevated in the LA- and MG-groups compared to CG. Multiple regression analysis revealed lipoprotein (a) values as a predictor for eGFR decline and increased proteinuria. Elevated lipoprotein (a) levels are associated with decreased eGFR and worse proteinuria, highlighting that regular monitoring and effective treatment, to date especially lipid apheresis, are of utmost importance to mitigate detrimental effects on renal function.<\/jats:p>","DOI":"10.1097\/md.0000000000044131","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:01:23Z","timestamp":1756494083000},"page":"e44131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of severe dyslipidemia on renal function: A cross-sectional study"],"prefix":"10.1097","volume":"104","author":[{"given":"Nicole","family":"Lewandowski","sequence":"first","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Spitth\u00f6ver","sequence":"additional","affiliation":[{"name":"Dialyse- und Lipidzentrum Nordrhein, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Boss","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-233X","authenticated-orcid":false,"given":"Nils","family":"M\u00fclling","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","article-title":"Cholesterol and the risk of renal dysfunction in apparently healthy men.","volume":"14","author":"Schaeffner","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population.","volume":"291","author":"Fox","year":"2004","journal-title":"JAMA"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","article-title":"Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.","volume":"58","author":"Muntner","year":"2000","journal-title":"Kidney Int"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"159063","DOI":"10.1016\/j.bbalip.2021.159063","article-title":"HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease \u2013 insights from randomized clinical trials and human genetics.","volume":"1867","author":"Kjeldsen","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2013050482","article-title":"HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.","volume":"25","author":"Zewinger","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosissup.2015.02.012","article-title":"Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease \u2013 additional particular aspects of the Pro(a)LiFe multicenter trial.","volume":"18","author":"Klingel","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosissup.2015.02.013","article-title":"Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany.","volume":"18","author":"Heigl","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"R13-20260406","first-page":"312","article-title":"Lipid management in patients with type 2 diabetes.","volume":"4","author":"Daniel","year":"2011","journal-title":"Am Health Drug Benefits"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.atherosclerosis.2007.06.018","article-title":"Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA).","volume":"197","author":"de Boer","year":"2008","journal-title":"Atherosclerosis"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/ATVBAHA.108.168690","article-title":"High-density lipoprotein reduces the human monocyte inflammatory response.","volume":"28","author":"Murphy","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5455\/medarh.2019.73.154-156","article-title":"Serum creatinine and occurrence and severity of coronary artery disease.","volume":"73","author":"Bagheri","year":"2019","journal-title":"Med Arch"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2169\/internalmedicine.4503-20","article-title":"Lipoprotein (a) and the risk of chronic kidney disease in hospitalized Japanese patients.","volume":"59","author":"Tada","year":"2020","journal-title":"Intern Med"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1194\/jlr.RA120000771","article-title":"Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation.","volume":"61","author":"Xuan","year":"2020","journal-title":"J Lipid Res"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12882-018-0986-2","article-title":"Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease.","volume":"19","author":"Ma","year":"2018","journal-title":"BMC Nephrol"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans.","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"106936","DOI":"10.1016\/j.phrs.2023.106936","article-title":"European guidelines for the treatment of dyslipidaemias: new concepts and future challenges.","volume":"196","author":"Pirillo","year":"2023","journal-title":"Pharmacol Res"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10654-009-9346-7","article-title":"Serum gamma-glutamyl transferase level and diabetes mellitus among US adults.","volume":"24","author":"Sabanayagam","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease.","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"102615","DOI":"10.1016\/j.eclinm.2024.102615","article-title":"Projecting the economic burden of chronic kidney disease at the patient level (inside CKD): a microsimulation modelling study.","volume":"72","author":"Chadban","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"sfae032","DOI":"10.1093\/ckj\/sfae032","article-title":"Renal function alters the association of lipoprotein(a) with cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a prospective cohort study.","volume":"17","author":"Zeng","year":"2024","journal-title":"Clin Kidney J"},{"key":"R26-20260406","first-page":"397","article-title":"Lipoprotein(a) is a prevalent yet vastly underrecognized risk factor for cardiovascular disease.","volume":"12","author":"Rendler","year":"2024","journal-title":"Health Care Curr Rev"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"e0284103","DOI":"10.1371\/journal.pone.0284103","article-title":"Use of machine learning to identify risk factors for coronary artery disease.","volume":"18","author":"Huang","year":"2023","journal-title":"PLoS One"},{"key":"R28-20260406","doi-asserted-by":"crossref","first-page":"e0281922","DOI":"10.1371\/journal.pone.0281922","article-title":"Increasing transparency in machine learning through bootstrap simulation and shapely additive explanations.","volume":"18","author":"Huang","year":"2023","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:02:34Z","timestamp":1775455354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":28,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044131","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2025-04-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}